Canada Pension Plan Investment Board Buys New Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Canada Pension Plan Investment Board bought a new stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) during the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 2,200 shares of the company’s stock, valued at approximately $151,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Covestor Ltd raised its holdings in shares of Prestige Consumer Healthcare by 21.6% during the 1st quarter. Covestor Ltd now owns 834 shares of the company’s stock worth $61,000 after acquiring an additional 148 shares in the last quarter. Miller Howard Investments Inc. NY raised its holdings in shares of Prestige Consumer Healthcare by 2.2% during the 2nd quarter. Miller Howard Investments Inc. NY now owns 7,762 shares of the company’s stock worth $534,000 after acquiring an additional 165 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Prestige Consumer Healthcare by 80.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after acquiring an additional 208 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of Prestige Consumer Healthcare by 42.5% during the 4th quarter. Parallel Advisors LLC now owns 714 shares of the company’s stock worth $44,000 after acquiring an additional 213 shares in the last quarter. Finally, QRG Capital Management Inc. raised its holdings in shares of Prestige Consumer Healthcare by 4.7% during the 2nd quarter. QRG Capital Management Inc. now owns 5,397 shares of the company’s stock worth $372,000 after acquiring an additional 242 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PBH. DA Davidson upped their price objective on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Jefferies Financial Group reaffirmed a “hold” rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $94.20.

Prestige Consumer Healthcare Stock Performance

NYSE PBH opened at $71.32 on Friday. The company has a market cap of $3.53 billion, a P/E ratio of 17.10, a P/E/G ratio of 2.01 and a beta of 0.48. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.90 and a current ratio of 3.23. The business’s 50 day moving average price is $71.21 and its 200-day moving average price is $69.63. Prestige Consumer Healthcare Inc. has a fifty-two week low of $56.34 and a fifty-two week high of $75.80.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.04. The firm had revenue of $267.10 million for the quarter, compared to the consensus estimate of $260.54 million. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. The company’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.06 EPS. Sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.43 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.